FORT WORTH, Texas, May 21 -- Kenny Perry was named this week's CRESTOR(R) (rosuvastatin calcium) Charity Challenge winner for his first-place standing entering the final round of the Bank of America Colonial. The CRESTOR(R) Charity Challenge is a season-long competition that recognizes and rewards the tournament leader entering the final round at 35 PGA TOUR events. Through the program, now in its second year, AstraZeneca will donate $3.5 million a year to designated health and PGA TOUR charities. At each of the selected tournaments, a $100,000 contribution will be made, supporting the PGA TOUR's "Drive to a Billion" campaign which celebrates the spirit of giving that has helped the TOUR and its tournaments approach the milestone of $1
billion dollars in charitable giving.
(Photo: http://www.newscom.com/cgi-bin/prnh/20050521/NYSA001 )

For Perry's performance, CRESTOR, an AstraZeneca pharmaceutical product, and the Bank of America Colonial will donate $50,000 to the Cook Children's Medical Center. In addition, $50,000 will be donated to the health care charity of Perry's choice. CRESTOR(R) Charity Challenge winners and the tournament's designated charity will be recognized during the network or cable telecast of each tournament.

Last year, Chad Campbell, Brian Gay, Steve Flesch, were tied for the lead entering the final round of the Bank of America Colonial. For their performance, AstraZeneca donated $50,000 to Cook Children's Medical Center. Campbell, Gay and Flesch split their charitable $50,000 donation to Cook Children's Medical Center (Campbell); the Florida Hospital Foundation and Orlando Regional Healthcare Foundation (Gay); and St. Elizabeth Medical Center (Flesch). Cook Children's Medical Center has received $116,667 over the past two years.

"We're pleased to have the support of Crestor and AstraZeneca and be a part of the CRESTOR(R) Charity Challenge for the second consecutive year,"said Russell K. Tolman, president and CEO of Cook Children's Health Care System.

"Cook Children's touches the lives of about 1 million children each year, including those treated in our heart center. We appreciate businesses and other donors who help us provide sophisticated care to the children of Fort Worth, north Texas and surrounding states."

The CRESTOR(R) Charity Challenge is the centerpiece of a multi-year PGA
TOUR partnership with AstraZeneca (NYSE: AZN). Last year, AstraZeneca donated
$2.7 million through the program. Highlights from the 2004 CRESTOR(R) Charity
Challenge included:

-- More than 50 charities benefited from the program.
-- Vijay Singh topped more than one money list in 2004, leading all
players with five CRESTOR(R) Charity Challenge wins.
-- Tom Lehman was the only player to win three straight CRESTOR(R) Charity
Challenges.
-- Adam Scott, who won twice, was the only other multiple winner.
-- 17 CRESTOR(R) Charity Challenge winners went on to victory in their
respective tournaments.

"After just one year, the CRESTOR(R) Charity Challenge has become a
visible extension of the PGA TOUR's mission of giving back in local
communities throughout America," said Tony Zook, senior vice president,
commercial operations, AstraZeneca U.S. "Through AstraZeneca's support, the
CRESTOR(R) Charity Challenge will play a major role in the PGA TOUR's "Drive
to a Billion" charitable program."

Fans can log on to http://www.crestor.pgatour.com to read about past
CRESTOR(R) Charity Challenge winners and learn more about CRESTOR. CRESTOR is
the presenting sponsor of TOUR Fantasy Golf at pgatour.com/fantasy and the PGA
TOUR's year-end charity special that will air in December.

About Cook Children's Healthcare System
The Cook Children's Healthcare System is an integrated delivery
organization dedicated to providing quality healthcare and to improving the
well-being of children. It provides more than 30 pediatric specialties and
services, plus nationally-recognized services for newborns and for children
with heart problems, cancer and lung ailments. The CRESTOR Charity Challenge
will help to benefit the Cook Children's Heart Center, which includes
pediatric cardiology, pediatric cardiothoracic surgery and an eight-bed
Cardiac Intensive Care Unit.

About CRESTOR
CRESTOR (rosuvastatin calcium) is a once-daily prescription medication for
use as an adjunct to diet in the treatment of various lipid disorders
including primary hypercholesterolemia, mixed dyslipidemia and isolated
hypertriglyceridemia. It is a member of the statin (HMG-CoA reductase
inhibitors) class of drug therapy. CRESTOR has not been determined to prevent
heart disease, heart attacks, or strokes. For patients with
hypercholesterolemia and mixed dyslipidemia, the usual recommended starting
dose of CRESTOR is 10 mg. Initiation of therapy with 5 mg once daily should
be considered for patients requiring less aggressive LDL-C reductions or who
have predisposing factors for myopathy. For patients with marked
hypercholesterolemia (LDL-C >190 mg/dL) and aggressive lipid targets, a 20-mg
starting dose may be considered. AstraZeneca licensed worldwide rights to
CRESTOR from the Japanese pharmaceutical company Shionogi & Co., Ltd.

Important Safety Information
CRESTOR is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases, in women who are pregnant or may become pregnant, and in nursing mothers. It is recommended that liver function tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with CRESTOR and with other drugs in this class. The 40-mg dose of CRESTOR is reserved for those patients who have not achieved LDL-C goal at 20 mg. CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy,
such as renal impairment. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CRESTOR is generally well-tolerated. Adverse reactions have usually been mild and transient. The most frequent adverse events thought to be related to CRESTOR were myalgia (3.3%), constipation (1.4%), asthenia (1.3%), abdominal pain (1.3%) and nausea (1.3%). A full copy of the prescribing information for CRESTOR is available at http://www.astrazeneca-us.com/pi/crestor.pdf or by calling 1-877-420-7249.

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $21.4 billion and leading positions in sales of gastrointestinal, cardiovascular, respiratory, oncology and neuroscience products. In the United States,
AstraZeneca is a $9.6 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index. For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com

SOURCE AstraZeneca
Web Site: http://www.astrazeneca-us.com
http://www.crestor.pgatour.com
Photo Notes: NewsCom:
http://www.newscom.com/cgi-bin/prnh/20050521/NYSA001 AP Archive:
http://photoarchive.ap.org PRN Photo Desk,
photodesk@prnewswire.com